Summit Therapeutics Says Ivonescimab Combination Extends Progression-Free Survival in Lung Cancer Patients
Summit Therapeutics reported positive Phase 3 trial results for ivonescimab, extending progression-free survival in lung cancer patients.
Summit Therapeutics tested a cancer medicine that helped lung cancer patients stay healthier longer in a big test. When a company's medicine works better than expected, people pay more attention to that company's stock because it might do well in the future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.